In particular, in cases showing translocation of MYC alone, tumor progression and survival may be under the control of distinct anti‐apoptotic BCL2‐family proteins, against which specific pharmacological inhibitors are also available [21]: the latter compounds—rather than venetoclax—may thus show synergy with IACS‐010759 in these tumors. The gene discussed is BCL2; the disease is neoplasm.